Ian A Strohbehn
Overview
Explore the profile of Ian A Strohbehn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Potluri V, Goldberg D, Zhang S, Schaubel D, Molnar M, Forbes R, et al.
Transpl Infect Dis
. 2025 Mar;
:e70011.
PMID: 40047349
Background: Several studies have suggested an increased risk of cytomegalovirus (CMV) viremia among Hepatitis C virus (HCV)-uninfected recipients of kidney transplants from HCV-RNA+ deceased donors (HCV D+/R-), but these studies...
2.
Strohbehn I, Ouyang T, Lee M, Zhao S, Harden D, Mejia S, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofae756.
PMID: 39872811
Background: Patients with kidney disease are at high risk for adverse outcomes after coronavirus disease 2019 (COVID-19) despite vaccination. Because patients with advanced chronic kidney disease (CKD) and kidney failure...
3.
Wang Q, Seethapathy R, Ouyang T, Strohbehn I, Katz-Agranov N, Hanna P, et al.
Kidney Int Rep
. 2023 Dec;
8(12):2833-2837.
PMID: 38106586
No abstract available.
4.
Hanna P, Strohbehn I, Moreno D, Harden D, Seethapathy R, Sawtell R, et al.
NPJ Breast Cancer
. 2023 Aug;
9(1):70.
PMID: 37598278
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown....
5.
Hanna P, Wang Q, Strohbehn I, Moreno D, Harden D, Ouyang T, et al.
JAMA Netw Open
. 2023 Jul;
6(7):e2321715.
PMID: 37405775
Importance: Serum creatinine-based estimated glomerular filtration rate (eGFRcr) may overestimate the glomerular filtration rate (GFR) in patients with cancer. Cystatin C-based eGFR (eGFRcys) is an alternative marker of GFR. Objective:...
6.
Sise M, Katz-Agranov N, Strohbehn I, Harden D, Moreno D, Durbin C, et al.
J Acquir Immune Defic Syndr
. 2023 May;
94(1):53-56.
PMID: 37229530
Background: Sodium-glucose transporter 2 (SGLT2) inhibitors have been approved for treatment of diabetes mellitus (DM), chronic kidney disease, and heart failure, but little is known about prescription levels and safety...
7.
Seethapathy R, Wang Q, Zhao S, Strohbehn I, Long J, Dinulos J, et al.
PLoS One
. 2023 Feb;
18(2):e0279765.
PMID: 36848366
Background: Chronic kidney disease (CKD) is an important risk factor for mortality from COVID-19. Remdesivir has been shown to shorten time to recovery in patients with severe COVID-19. However, exclusion...
8.
Tiu B, Strohbehn I, Zhao S, Ouyang T, Hanna P, Wang Q, et al.
Oncologist
. 2023 Feb;
28(6):e379-e390.
PMID: 36821637
Background: Clinical trials of immune checkpoint inhibitors (ICIs) often do not include patients with advanced chronic kidney disease (CKD). We aimed to determine the safety of ICIs in patients with...
9.
Wang Q, Strohbehn I, Zhao S, Seethapathy H, Strohbehn S, Hanna P, et al.
Kidney Int Rep
. 2022 Dec;
7(11):2517-2521.
PMID: 36531890
No abstract available.
10.
Gupta S, Strohbehn I, Wang Q, Hanna P, Seethapathy R, Prosek J, et al.
Kidney Int
. 2022 Aug;
102(4):930-935.
PMID: 35964800
No abstract available.